Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olipudase alfa - Sanofi

Drug Profile

Olipudase alfa - Sanofi

Alternative Names: Acid sphingomyelinase Niemann Pick disease type B - Sanofi; Acid-sphingomyelinase - Sanofi; GZ-402665; Recombinant human acid sphingomyelinase - Sanofi; rhASM - Sanofi; Sphingomyelinase-C (synthetic human) - Sanofi; Synthetic human sphingomyelinase-C - Sanofi; XENPOZYME; Xenpozyme

Latest Information Update: 25 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi
  • Class Recombinant proteins; Sphingomyelin phosphodiesterases
  • Mechanism of Action Sphingomyelin-phosphodiesterase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Niemann-Pick diseases
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Niemann-Pick diseases

Most Recent Events

  • 05 Mar 2024 Launched for Niemann-Pick diseases (In adolescents, In children, In adults) in United Kingdom, Cyprus, Italy, Austria, Germany (IV)
  • 05 Mar 2024 National Institute for Health and Care Excellence (NICE) decides not to recommend olipudase alfa in Niemann-Pick diseases
  • 10 Nov 2023 Pooled efficacy data from a phase-II/II ASCEND, phase I/II ASCEND-Peds and phase I trial in Niemann-Pick diseases presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top